TNFRSF4 and neoplasm: One other agent, OX40 or its ligand (OX40L), a costimulatory molecule that activates T cells (147), has been explored in combination with OVs (148, 149), but an increased T-cell response was not transferred to corresponding tumor inhibition when an OX40 agonist was combined with VSV-IFNβ (149).